Monday, July 15, 2024

Expert panel gives nod to US weight loss drug in India

Tirzepatide Drug Likely to Launch in India: Approval Pending

The popular weight loss and diabetes drug Tirzepatide, known as Mounjaro and Zepbound in the US, is poised to enter the Indian market after receiving approval from the apex drug regulator’s expert committee. Although an official launch date has not been confirmed, the drug is expected to be available soon pending final approval from the Drug Controller General of India (DCGI).

The committee has given the green light for the import and marketing of Tirzepatide in six different doses, ranging from 2.5 mg to 12.5 mg. If introduced, it will be the first drug of its category to be available in India. While the oral version of competitor Novo Nordisk’s Semaglutide is already approved for diabetes management in India, the higher dose injectable version for weight loss has yet to be launched.

In a statement to The Indian Express, Eli Lilly mentioned that they have received marketing authorization for the Type 2 Diabetes indication for Tirzepatide in India, with the application for obesity indication currently under review. The launch timelines for India are still pending confirmation.

The approval from the expert committee was based on two global clinical trials, including a significant number of participants from India. However, concerns remain about the long-term impacts of the drug and the affordability for potential users. Doctors are advised to carefully select patients for prescribing Tirzepatide, considering factors such as medical history and potential side effects.

While the drug holds promise for individuals struggling with weight loss and diabetes management, further research and monitoring will be necessary to assess its effectiveness and safety in the Indian population. Stay tuned for updates on the official launch of Tirzepatide in India.

Related Articles

Latest Articles

Most Popular